Physician profile
Sabrina Uddin
NPI 1407275217
$7,625.65
in general payments reported to CMS, 2019-2025
26 companies · $2,084 in 2025
The $2,084 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,609 · 2020: $368 · 2021: $283 · 2022: $735 · 2023: $1,052 · 2024: $1,494 · 2025: $2,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,531 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,531.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,071.14 | 2019-2025 | Skyrizi, Botox |
| Novartis Pharmaceuticals Corporation | $932.99 | 2019-2025 | |
| Genzyme Corporation | $836.98 | 2019-2025 | |
| Galderma Laboratories, L.P. | $658.87 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $541.35 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $475.93 | 2019-2025 | Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $475.90 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $437.10 | 2019-2025 | Dupixent |
| Ucb, INC. | $408.69 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $345.91 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $298.89 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $248.52 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $147.97 | 2020-2025 | Otezla, Otezla |
| Journey Medical Corporation | $136.37 | 2022-2025 | |
| Dermavant Sciences, INC. | $107.44 | 2024 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $97.33 | 2019 | |
| Mayne Pharma Commercial LLC | $78.84 | 2019 | |
| Almirall LLC | $75.02 | 2024 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.61 | 2019-2024 | Duobrii, Siliq |
| Sanofi-Aventis U.S. LLC | $47.14 | 2019 | |
| Arcutis Biotherapeutics, INC. | $41.52 | 2023-2024 | Zoryve |
| Organon LLC | $24.85 | 2025 | Vtama |
| Celgene Corporation | $24.06 | 2019 | |
| Cipher Pharmaceuticals US LLC | $20.33 | 2025 | Spinosad, Natroba |
| Genentech USA, INC. | $19.97 | 2019 | |
| Dermira, INC. | $15.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.